Servier Completes DAWN Acquisition After 85.34% Tender, Initiates Delisting

Context The pharmaceutical sector often sees consolidation as larger companies acquire smaller entities to expand portfolios or secure new technologies. Such mergers typically involve tender offers, where an acquirer offers to purchase shares directly from shareholders, followed by a formal merger process. This strategy allows for swift integration, bypassing lengthy proxy solicitations common in traditional mergers.

Key Facts Servier completed its acquisition of Day One Biopharmaceuticals on April 23, 2026. The transaction concluded through a short-form merger process under Section 251(h) of Delaware corporate law. This legal provision enables a quick merger after a successful tender offer without requiring a separate shareholder vote. The tender offer saw 88.18 million shares, representing 85.34% of Day One Biopharmaceuticals' outstanding shares, validly tendered. This acceptance threshold allowed Servier to proceed with the merger. Following the merger's finalization, Servier requested the delisting of Day One Biopharmaceuticals' shares from Nasdaq via Form 25. The company also intends to file Form 15 to terminate its public reporting obligations, effectively ending its status as a publicly traded entity.

What It Means The completion of this acquisition means Day One Biopharmaceuticals is now a wholly-owned subsidiary of Servier. Its shares will no longer trade on Nasdaq, and its public reporting duties to the Securities and Exchange Commission will cease once Form 15 is filed. For remaining shareholders who did not tender their shares, their holdings converted into the offer price at the effective time of the merger. The transition removes Day One Biopharmaceuticals from public market scrutiny, allowing Servier to integrate its operations and assets internally. Watch for the finalization of the delisting process and the timeline for Servier's integration of Day One Biopharmaceuticals' assets and operations.